Clinical Trial

Effects of Intrauterine Administration of Autologous PBMC Modulated With IFNt on Endometrial Cell Populations

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 21, 2025 (before its estimated March 14, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this clinical trial is to investigate the change in endometrial composition during the window of implantation following intrauterine administration of PBMC immunomodulated with IFNt. Patients seeking assisted reproductive therapy will be invited to participate. Two endometrial biopsies will be obtained from each patient during mid-secretory phase of two consecutive menstrual cycles. The first biopsy will be obtained one month before the intervention, and the second one - a day after intrauterine administration of the tested cell treatment which will take place the following month. Immunohistochemistry analysis of the cell composition of the endometrium will be performed.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-03-07; most recent amendment 2025-05-20.
Trial Details
NCT Number NCT05775211
Lead Sponsor Nadezhda Women's Health Hospital
Conditions Infertility
Enrollment 300 participants
Start Date 2023-03-13
Primary Completion 2026-03-14 (estimated)
Study Completion 2026-04-28 (estimated)
Updated on ClinicalTrials.gov 2025-05-21